Precision therapy targeting CAMK2 to overcome resistance to EGFR inhibitors in FAT1-mutated oral squamous cell carcinoma
Combination therapy with EGFR inhibitors and KN93 could be a novel precision therapeutic strategy and a potential clinical solution for EGFR-resistant OSCC patients with FAT1 mutations.
Authors
- Yingqiang Shen (ORCID: https://orcid.org/0000-0002-9727-7959)
- Jing Li (ORCID: https://orcid.org/0000-0001-7792-4322)
- You Zhang (ORCID: https://orcid.org/0000-0001-5757-2657)
- Ning Ji (ORCID: https://orcid.org/0000-0002-2896-5205)
- Yibo Huang (ORCID: https://orcid.org/0000-0001-5373-6546)
- Yu Zhou (ORCID: https://orcid.org/0000-0003-1844-2045)
- Bowen Yang (ORCID: https://orcid.org/0000-0003-4846-6945)
- Qianming Chen
- Yumeng Lin
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Sichuan University (CN)
Publication Details
- Journal
- Chinese Medical Journal
- Published
- 2024-09-03
- DOI
- https://doi.org/10.1097/cm9.0000000000003217
- Citations
- 5
- Primary Topic
- Ubiquitin and proteasome pathways
- Type
- article
- Field-Weighted Citation Impact
- 1.17